ETOP IBCSG Partners Foundation
ETOP IBCSG Partners Foundation
Explore linked clinical trials.17 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-07 | NCT05512364 | |
| Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-10-05 | NCT03965468 | |
| A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-28 | NCT06931717 | |
| A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 | Extensive Stage Lung Small Cell Cancer | Recruiting | Phase 2 | 2026-09-21 | NCT07203053 | |
| Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-09-03 | NCT05673187 | |
| Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | Breast Cancer Recurrent | Active, not recruiting | Phase 3 | 2026-09-03 | NCT03820830 | |
| Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC | SCLC,Extensive Stage; SLFN11-positive | Recruiting | Phase 2 | 2026-05-29 | NCT05718323 | |
| Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Thymus Neoplasms, lymphatic system disorder, mixed neoplasm, neoplasm, thymoma, thymoma type B3 | Active, not recruiting | Phase 2 | 2026-05-15 | NCT03134118 | |
| A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-05-14 | NCT06284317 | |
| Adjuvant Palbociclib in Elderly Patients With Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-05-12 | NCT03609047 | |
| Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not applicable | 2026-05-01 | NCT03513614 | |
| Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 3 | 2026-04-27 | NCT05522660 | |
| Sacituzumab Govitecan in Primary HER2-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-04-22 | NCT04595565 | |
| Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not applicable | 2026-02-09 | NCT02308085 | |
| Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-01-21 | NCT05601973 | |
| EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not applicable | 2025-09-18 | NCT02889874 | |
| Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2025-09-08 | NCT05063786 |